Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Trial to Assess the Efficacy and Safety of Apremilast in the Management of Vision-threatening Uveitis That is Refractory to Other Modes of Systemic Immunosuppression.

NCT00889421 is registered in ClinicalTrials.gov with Oregon Health and Science University as lead sponsor.

NCT NCT00889421
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00889421 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Trial to Assess the Efficacy and Safety of Apremilast in the Management of Vision-threatening Uveitis That is Refractory to Other Modes of Systemic Immunosuppression.
Lead sponsor
Oregon Health and Science University
Phase
Phase 1/2
Overall status
Terminated
Start date
November 30, 2009
Completion date
June 30, 2011
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

uveitis